KR101936969B1 - Liquid composition for oral cavity and method for stable addition of components to composition - Google Patents

Liquid composition for oral cavity and method for stable addition of components to composition Download PDF

Info

Publication number
KR101936969B1
KR101936969B1 KR1020137022621A KR20137022621A KR101936969B1 KR 101936969 B1 KR101936969 B1 KR 101936969B1 KR 1020137022621 A KR1020137022621 A KR 1020137022621A KR 20137022621 A KR20137022621 A KR 20137022621A KR 101936969 B1 KR101936969 B1 KR 101936969B1
Authority
KR
South Korea
Prior art keywords
composition
component
mass
chloride
liquid oral
Prior art date
Application number
KR1020137022621A
Other languages
Korean (ko)
Other versions
KR20140007406A (en
Inventor
나오코 카와구치
Original Assignee
라이온 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라이온 가부시키가이샤 filed Critical 라이온 가부시키가이샤
Publication of KR20140007406A publication Critical patent/KR20140007406A/en
Application granted granted Critical
Publication of KR101936969B1 publication Critical patent/KR101936969B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/345Alcohols containing more than one hydroxy group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41Amines
    • A61K8/416Quaternary ammonium compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/731Cellulose; Quaternized cellulose derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30Characterized by the absence of a particular group of ingredients

Abstract

플라그의 부착 억제 효과 및 플라그 중의 뮤탄스균 살균력에 우수하면서도, 외관 안정성이 향상하고 기호성도 양호한, 에탄올을 함유하지 않은 액체 구강용 조성물을 제공한다. 에탄올을 실질적으로 함유하지 않은 액체 구강용 조성물에, (A) 카티온성 살균제 및 (B) 히드록시에틸셀룰로스디메틸디알릴암모늄클로리드를 배합함과 함께, (C) 아네톨을 (C)성분/[(A)성분+(B)성분]이 질량비로서 0.1 내지 10이 되는 범위에서 병용하고, 또한 (D) 다가알코올 및/또는 (E) 비이온성 계면활성제를 배합한 것을 특징으로 하는 액체 구강용 조성물. 상기 액체 구강용 조성물에, (A) 및 (B)성분을 배합함과 함께, (C)성분을 (C)/[(A)+(B)]가 0.1 내지 10이 되는 범위에서 병용하고, (D) 및/또는 (E)성분을 배합하고, 상기 조성물에 (A) 및 (B)성분을 안정화 배합하는 방법.Provided is a liquid oral composition which does not contain ethanol, which is excellent in the adhesion inhibition effect of plaques and the microbicidal disinfecting power in plaques, but also has excellent appearance stability and good palatability. (A) a cationic fungicide and (B) hydroxyethyl cellulose dimethyldiallylammonium chloride, (C) adding anethole to the liquid oral composition substantially free of ethanol as component (C) (D) a polyhydric alcohol and / or (E) a non-ionic surfactant in combination in a ratio of [Component (A) + Component (B)] in the range of 0.1 to 10 in mass ratio. Composition. (A) and (B) are added to the liquid oral composition and the component (C) is used in combination in a range of from 0.1 to 10 (C) / [(A) + (B) (D) and / or (E), and stabilizing the components (A) and (B) in the composition.

Description

액체 구강용 조성물 및 그 조성물에 성분을 안정화 배합하는 방법{LIQUID COMPOSITION FOR ORAL CAVITY AND METHOD FOR STABLE ADDITION OF COMPONENTS TO COMPOSITION}TECHNICAL FIELD [0001] The present invention relates to a liquid oral composition and a method for stabilizing a composition in the composition.

본 발명은, 우수한 치면(齒面)에의 플라그 부착 억제 효과 및 플라그 중의 뮤탄스균(菌) 살균력을 이루면서도, 외관 안정성(앙금(オリ)이 없음)이 향상하고 기호성도 양호한, 에탄올을 함유하지 않은 액체 구강용 조성물 및 그 조성물에 성분을 안정화 배합하는 방법에 관한 것이다.An object of the present invention is to provide a pharmaceutical composition which is excellent in palatability to plaque and has excellent microbial sterilizing power in plaque and excellent appearance stability (no sediment) and excellent palatability, Liquid oral composition and a method of stabilizing and compounding the composition in the composition.

치주병이나 유식의 예방에는 플라그의 억제가 중요하고, 플라그 억제를 목적으로 하여 살균제를 배합한 구강용 조성물이 널리 사용되고 있다. 이들의 살균제 중에서 카티온성 살균제는, 구강 세균의 살균 효과, 플라그 억제 효과, 치육염 개선 효과를 갖기 때문에 널리 사용되고 있다. 또한, 히드록시에틸셀룰로스디메틸디알릴암모늄클로리드는 치아의 표면에 흡착하기 쉬운 성질을 갖고 있고, 이것을 사용하여 플라그 형성을 효과적으로 억제할 수 있는 액체 구강용 조성물이 특허 문헌 1(일본국 특개2001-64137호 공보)에 제안되어 있다. 또한, 카티온성 폴리머를 카티온성 살균제인 염화세틸피리디늄(CPC) 등과 조합함으로써 플라그의 부착 억제 효과가 상승적으로 향상하는 것 등이 알려져 있다(특허 문헌 2 ; 일본국 특개2000-34213호 공보). 또한, 히드록시에틸셀룰로스디메틸디알릴암모늄클로리드와 카티온성 살균제와의 병용은 공지로서, 여러가지의 관련 기술이 제안되어 있다(특허 문헌 3 ; 일본국 특개2001-139442호 공보, 특허 문헌 4 ; 일본국 특개2001-139443호 공보).In order to prevent periodontal diseases and ingestion, suppression of plaque is important, and oral compositions containing a bactericide for plaque inhibition are widely used. Of these fungicides, cationic fungicides are widely used because they have a sterilizing effect of oral bacteria, an effect of suppressing plaque, and an effect of improving dental floss. Further, hydroxyethyl cellulose dimethyldiallylammonium chloride has a property of being easily adsorbed on the surface of teeth, and a liquid oral composition capable of effectively suppressing formation of plaque by using the composition is disclosed in Patent Document 1 (Japanese Patent Laid- 64137). In addition, it is known that the adhesion inhibition effect of plaque is synergistically improved by combining a cationic polymer with cetylpyridinium chloride (CPC), which is a cationic fungicide, and the like (Patent Document 2: Japanese Patent Application Laid-Open No. 2000-34213). In addition, a combination of hydroxyethyl cellulose dimethyldiallylammonium chloride and a cationic fungicide is known and various related arts have been proposed (Japanese Patent Application Laid-Open No. 2001-139442, Patent Document 4, Japanese Patent Laid- 2001-139443).

선행의 기술은 모두 에탄올의 배합을 허용하는 것인데, 근래, 저자극의 사용감이 요구되는 중에서, 알코올에 의한 자극이 생기는 것에 문제가 있어서, 논알코올의 조성이 요망되는 경향에 있다.All of the foregoing prior arts allow the blending of ethanol. In recent years, there has been a problem in that irritation due to alcohol has occurred in a feeling of feeling of low stimulation, and the composition of the non-alcohol tends to be desired.

그러나, 에탄올을 배합하지 않는 경우, 카티온성 살균제와 히드록시에틸셀룰로스디메틸디알릴암모늄클로리드를 배합한 조성에서는 외관 안정성의 확보가 어려워, 자극의 없음과 외관의 경시 안정성을 동시에 확보하는 것은 곤란하다는 문제가 있다. 또한, 카티온성 살균제와 히드록시에틸셀룰로스디메틸디알릴암모늄클로리드에 유래하는 떫은맛(澁味)·쓴맛(苦味)·이상한맛(異味)이 생기는 일도 있어서, 양 성분의 효과와 제제의 기호성(嗜好性)을 양립시키는 것은 어려웠다.However, in the case where ethanol is not blended, it is difficult to secure the appearance stability in the composition comprising the cationic fungicide and hydroxyethyl cellulose dimethyldiallylammonium chloride, and it is difficult to secure both the irritation and the stability of the appearance over time there is a problem. In addition, there is a case where a bitter taste, a bitter taste, or an unpleasant taste derived from a cationic bactericide and hydroxyethyl cellulose dimethyldiallylammonium chloride occurs, and the effect of both components and the palatability of the preparation Sex).

특허 문헌 1 : 일본국 특개2001-64137호 공보Patent Document 1: JP-A-2001-64137 특허 문헌 2 : 일본국 특개2000-34213호 공보Patent Document 2: Japanese Patent Application Laid-Open No. 2000-34213 특허 문헌 3 : 일본국 특개2001-139442호 공보Patent Document 3: Japanese Patent Application Laid-Open No. 2001-139442 특허 문헌 4 : 일본국 특개2001-139443호 공보Patent Document 4: Japanese Patent Application Laid-Open No. 2001-139443

따라서 에탄올을 함유하지 않은 액체 제제에 카티온성 살균제와 히드록시에틸셀룰로스디메틸디알릴암모늄클로리드를 안정하게 배합하고, 외관 안정성을 확보하고, 또한 양 성분의 효과와 제제의 기호성을 양립할 수 있는 기술이 요망된다. 본 발명은, 상기 사정을 감안하다 이루어진 것으로, 플라그의 부착 억제 효과 및 플라그 중의 뮤탄스균 살균력에 우수하면서도, 외관 안정성이 향상하고 기호성도 양호한, 에탄올을 실질적으로 함유하지 않은 액체 구강용 조성물 및 그 조성물에의 성분의 안정화 배합 방법을 제공하는 것을 목적으로 한다.Therefore, a technique capable of stably mixing a cationic fungicide and hydroxyethyl cellulose dimethyldiallylammonium chloride in a liquid preparation containing no ethanol to ensure appearance stability, and to make both the effects of both components and palatability of the preparation both compatible Is desired. Disclosure of the Invention The present invention has been made in view of the above circumstances, and it is an object of the present invention to provide a composition for liquid oral cavity which is substantially free of ethanol and which is excellent in appearance stability and excellent in palatability, And to provide a method of stabilizing the components in the composition.

본 발명자는, 상기 목적을 달성하기 위해 예의 검토를 행한 결과, 에탄올을 실질적으로 함유하지 않은 액체 구강용 조성물에 (A) 카티온성 살균제 및 (B) 히드록시에틸셀룰로스디메틸디알릴암모늄클로리드를 배합함과 함께, (C) 아네톨을 (C)성분/[(A)성분+(B)성분]이 질량비로서 0.1 내지 10의 범위에서 배합하고, 또한 (D) 다가알코올 및/또는 (E) 비이온성 계면활성제를 배합함에 의해, 플라그의 부착 억제 효과와 플라그 중의 뮤탄스균 살균력에 우수하면서도, 배합함에 앙금의 발생을 억제하여 외관의 경시 안정성을 향상할 수 있고, 외관 안정성이 높고 기호성도 양호한 액체 제제를 얻을 수 있음을 지견하여, 본 발명을 이루는데 이르렀다.The inventors of the present invention have conducted intensive studies in order to achieve the above object, and as a result, the inventors of the present invention found that (A) a cationic bactericide and (B) hydroxyethyl cellulose dimethyldiallylammonium chloride were mixed in a liquid oral composition substantially free of ethanol (D) a polyhydric alcohol and / or (E) an anthole in an amount of 0.1 to 10 in terms of the mass ratio of the component (C) / [component (A) + component (B) By combining the nonionic surfactant, it is possible to improve the stability of the external appearance over time by suppressing the occurrence of sedimentation while being excellent in the adhesion inhibiting effect of plaques and the microbicidal disinfecting power in plaques, The inventors of the present invention have accomplished the present invention.

본 출원인은, 에탄올을 실질적으로 함유하지 않은 액체 구강용 조성물에, 카티온성 살균제와 카티온화셀룰로스를 배합하고, 또한 프로필렌글리콜, 폴리옥시에틸렌경화피마자유, 파라옥시안식향산에스테르를 배합한 액체 구강용 조성물이, 플라그의 부착 억제 효과 및 플라그 중의 뮤탄스균 살균력에 우수하면서도, 제제의 방부력과 외관 안정성에 우수한 것을 일본국 특원2010-280009(일본국 특개2011-148770호 공보)호에 제안하였다. 이 액체 구강용 조성물은 5℃에서 1개월 보존 후의 외관 안정성(앙금의 없음)에 우수한 것이다. 이에 대해, 본 발명자가 더욱 검토한 바, 에탄올을 포함하지 않는 액체 구강용 조성물에서는, 카티온성 살균제와 카티온화셀룰로스를 배합하는 경우, 제제 외관을 안정하게 유지하기가 어렵고, 특히 고온에서 장기에 걸쳐서 보존하면 앙금이 생기고 외관 안정성이 저하되는 것이 알고서, 카티온성 살균제와 카티온화셀룰로스를 보다 안정화할 수 있는 기술에 관해 검토를 진행하였다. 그 결과, 아네톨이, 의외에도 안정화제로서 유효하고, 에탄올을 함유하지 않은 액체 구강용 조성물에 카티온성 살균제와 히드록시에틸셀룰로스디메틸디알릴암모늄클로리드를 병용하여 배합하는 경우의 경시에서의 앙금을 억제하고, 외관 안정성의 향상에 기여하는 것, 따라서, 상기 양 성분을 병용한 조성에 아네톨을 적절하게 배합하고, 다가알코올 및/또는 비이온성 계면활성제를 배합함에 의해, 높은 외관 안정성을 확보할 수 있고, 또한 양 성분의 우수한 효과를, 이들 성분에 유래하는 떫은맛·쓴맛·이상한맛 등을 억제하여 양호한 기호성을 유지하고 발휘시킬 수 있음을 발견한 것이다.The present applicant has found that a liquid oral composition comprising a cationic fungicide and cationic cellulose and a propylene glycol, polyoxyethylene hydrogenated castor oil, and p-oxybenzoic acid ester in a liquid oral composition substantially free of ethanol Japanese Patent Application No. 2010-280009 (Japanese Patent Laid-Open Publication No. 2011-148770) proposes an antifouling coating composition which is excellent in antifouling effect of plaques and antimicrobial activity of microspheres in plaques and excellent in antifouling strength and appearance stability. This liquid oral composition is excellent in appearance stability (no sediment) after storage at 5 占 폚 for one month. On the other hand, the inventors of the present invention have found that, in the liquid oral composition containing no ethanol, when the cationic bactericide is mixed with the cationic cellulose, it is difficult to stably maintain the outer appearance of the preparation, The inventors of the present invention have studied a technique for stabilizing the cationic fungicide and the cationic cellulose by knowing that the preservation results in sedimentation and deterioration in appearance stability. As a result, it has been found that anethole is effective as a stabilizer even when unexpectedly, and when a composition for oral cavity containing no ethanol is mixed with a cationic bactericide and hydroxyethyl cellulose dimethyldiallylammonium chloride in combination, And therefore contributes to improvement in appearance stability. Therefore, by appropriately blending anethole in the composition in which both components are used in combination, and by blending a polyhydric alcohol and / or a nonionic surfactant, high appearance stability And excellent effects of the two components can be suppressed and the palatability, bitter taste, odd taste, etc. derived from these components can be suppressed and good palatability can be maintained and exerted.

아네톨이, 구강용 조성물에 항료로서 사용되는 것은 공지이지만, 에탄올을 배합하지 않는 액체 구강용 조성물에의 카티온성 살균제 및 히드록시에틸셀룰로스디메틸디알릴암모늄클로리드의 안정화 배합에 유효하고, 50℃에서 1개월 보존하여도 앙금이 거의 없는 높은 외관 안정성을 확보할 수 있고, 상기한 각별한 효과를 이루는 액체 제제를 얻을 수 있는 것은, 본 발명자의 새로운 지견이다.It is known that anethole is used as an antioxidant in oral compositions, but is effective for stabilizing formulation of a cationic bactericide and hydroxyethyl cellulose dimethyldiallylammonium chloride in a liquid oral composition not containing ethanol, It is possible to obtain a high appearance stability with little sedimentation even if it is stored for one month at a temperature of 100.degree. C. for 1 month, and it is a new knowledge of the present inventor that a liquid preparation achieving the above-mentioned remarkable effect can be obtained.

따라서 본 발명은 하기한 액체 구강용 조성물 및 그 조성물에의 성분의 안정화 배합 방법을 제공한다.Accordingly, the present invention provides a composition for liquid oral cavity as described below and a method for stabilizing components in the composition.

[I][I]

에탄올을 실질적으로 함유하지 않은 액체 구강용 조성물에, (A) 카티온성 살균제 및 (B) 히드록시에틸셀룰로스디메틸디알릴암모늄클로리드를 배합함과 함께, (C) 아네톨을 (C)성분/[(A)성분+(B)성분]이 질량비로서 0.1 내지 10이 되는 범위에서 병용하고, 또한 (D) 다가알코올 및/또는 (E) 비이온성 계면활성제를 배합한 것을 특징으로 하는 액체 구강용 조성물.(A) a cationic fungicide and (B) hydroxyethyl cellulose dimethyldiallylammonium chloride, (C) adding anethole to the liquid oral composition substantially free of ethanol as component (C) (D) a polyhydric alcohol and / or (E) a non-ionic surfactant in combination in a ratio of [Component (A) + Component (B)] in the range of 0.1 to 10 in mass ratio. Composition.

[Ⅱ][II]

에탄올을 실질적으로 함유하지 않은 액체 구강용 조성물에, (A) 카티온성 살균제 및 (B) 히드록시에틸셀룰로스디메틸디알릴암모늄클로리드를 배합함과 함께, (C) 아네톨을 (C)성분/[(A)성분+(B)성분]이 질량비로서 0.1 내지 10이 되는 범위에서 병용하고, 또한 (D) 다가알코올 및/또는 (E) 비이온성 계면활성제를 배합하고, 상기 액체 구강용 조성물에 (A) 및 (B)성분을 안정화 배합하는 방법.(A) a cationic fungicide and (B) hydroxyethyl cellulose dimethyldiallylammonium chloride, (C) adding anethole to the liquid oral composition substantially free of ethanol as component (C) (D) a polyhydric alcohol and / or (E) a nonionic surfactant in the range of 0.1 to 10 in terms of a mass ratio of the component (A) and the component (B) (A) and (B).

본 발명에 의하면, 플라그의 부착 억제 효과 및 플라그 중의 뮤탄스균 살균력에 우수하면서도, 외관 안정성이 향상하고 기호성도 양호한, 에탄올을 실질적으로 함유하지 않은 액체 구강용 조성물을 제공할 수 있다.INDUSTRIAL APPLICABILITY According to the present invention, it is possible to provide a liquid oral composition substantially free of ethanol, which is excellent in appearance stability and palatability, while being excellent in the effect of suppressing adhesion of plaques and the microbicidal disinfecting power in plaques.

이하, 본 발명에 대해 더욱 상세히 기술한다. 본 발명의 액체 구강용 조성물은, (A) 카티온성 살균제, (B) 히드록시에틸셀룰로스디메틸디알릴암모늄클로리드, (C) 아네톨, (D) 다가알코올 및/또는 (E) 비이온성 계면활성제를 함유한다.Hereinafter, the present invention will be described in more detail. The liquid oral composition of the present invention is characterized by comprising (A) a cationic bactericide, (B) hydroxyethyl cellulose dimethyldiallylammonium chloride, (C) anethole, (D) a polyhydric alcohol and / or (E) It contains an active agent.

(A)성분인 카티온성 살균제는, 치면에의 플라그의 부착을 억제하며 또한 플라그 중의 뮤탄스 세균을 살균하기 위한 유효 성분이다. 구체적으로는, 염화세틸피리디늄, 염화벤제토늄, 염화벤잘코늄 등을 들 수 있고, 이들 중의 1종을 단독으로 또는 2종 이상을 혼합하여 사용할 수 있다. 그중에서도, 살균력이나 핸들링성·사용성의 점에서 염화세틸피리디늄이 바람직하다.The cationic bactericide as the component (A) is an effective ingredient for inhibiting adhesion of the plaque to the tooth surface and sterilizing the mutant bacteria in the plaque. Specific examples thereof include cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride and the like, and one kind or a mixture of two or more kinds of them can be used. Among them, cetylpyridinium chloride is preferable in terms of sterilizing power, handling property and usability.

(A)성분인 카티온성 살균제의 배합량은, 치면에의 플라그 부착 억제, 플라그 중의 뮤탄스균 살균력의 점에서, 조성물 전체의 0.01 내지 0.1%(질량%. 이하 마찬가지), 특히 0.02 내지 0.05%가 바람직하다. 0.01% 미만에서는 치면에의 플라그 부착 억제 효과 및 플라그 중의 뮤탄스균 살균력이 만족하게 발휘되지 않는 경우가 있다. 0.1%를 초과하면 카티온성 살균제 유래의 떫은맛·쓴맛·이상한맛이 생기는 경우가 있다.The amount of the cationic fungicide as the component (A) is preferably from 0.01 to 0.1% (mass% or less), more preferably from 0.02 to 0.05%, of the whole composition from the viewpoints of suppression of plaque adhesion to the tooth surface and microbial sterilizing power in the plaque Do. If it is less than 0.01%, the effect of suppressing the attachment of the plaque to the tooth surface and the microbicidal activity of the microorganisms in the plaque may not be satisfactorily exhibited. If it is more than 0.1%, a bitter, bitter or strange taste originating from a cationic fungicide may be produced.

(B) 히드록시에틸셀룰로스디메틸디알릴암모늄클로리드는, 카티온성 폴리머이고, 치면에의 플라그 부착을 억제하기 위한 유효 성분으로서 배합된다. 상기 (A)성분인 카티온성 살균제와 함께 (B)성분을 배합함으로써, 치면에의 플라그의 부착 억제 효과가 향상하고, 또한 플라그 중의 뮤탄스 세균을 효과적으로 살균할 수 있고, 양 효과를 겸비함으로써, 높은 플라그 형성 억제 효과를 이룬다.(B) Hydroxyethyl cellulose Dimethyldiallylammonium chloride is a cationic polymer, and is compounded as an active ingredient for inhibiting the attachment of a plaque to a tooth surface. By combining the component (B) together with the cationic fungicide, which is the component (A), the effect of inhibiting adhesion of the plaque on the tooth surface can be improved, the mutant bacteria in the plaque can be effectively sterilized, High plaque formation inhibiting effect is achieved.

히드록시에틸셀룰로스디메틸디알릴암모늄클로리드는 시판품을 사용할 수 있고, 예를 들면 하기한 것을 예시할 수 있다.As the hydroxyethyl cellulose dimethyldiallylammonium chloride, a commercially available product can be used, and for example, the following can be exemplified.

·셀코트L-200(아크조노벨(주)제) :Cellcoat L-200 (manufactured by Akzo Nobel Co., Ltd.):

질소 함유량이 0.1 내지 3%이고 2% 수용액 점도가 30 내지 3,000mPa·s(BH형A nitrogen content of 0.1 to 3% and a viscosity of 2% aqueous solution of 30 to 3,000 mPa 占 퐏 (BH type

브록필드 점도계, 로터 No. 2, 20회전, 21℃, 측정 시간 1분)Brock Field Viscometer, Rotor No. 2, 20 revolutions, 21 캜, measuring time 1 min)

·셀코트H-100(아크조노벨(주)제) :Cellcoat H-100 (manufactured by Akzo Nobel Co., Ltd.):

질소 함유량이 1.0%이고 2% 수용액 점도가 500 내지 2,750mPa·s(BH형 브록필드 점도계, 로터 No. 2, 20회전, 21℃, 측정 시간 1분)A nitrogen content of 1.0% and a viscosity of 2% aqueous solution of 500 to 2,750 mPa · s (BH type Brookfield viscometer, rotor No. 2, 20 revolutions, 21 캜, measuring time of 1 minute)

(B)성분인 히드록시에틸셀룰로스디메틸디알릴암모늄클로리드의 배합량은, 조성물 전체의 0.005 내지 0.5%, 특히 0.01 내지 0.05%가 바람직하다. 0.005% 미만에서는 플라그 부착 억제 효과가 만족하게 발휘되지 않는 경우가 있다. 0.5%를 초과하면 앙금이 발생하여 외관 안정성(앙금의 없음)을 손상시키거나, 그것 유래의 떫은맛·쓴맛·이상한맛이 생겨서 사용감이 저하되는 경우가 있다.The blending amount of hydroxyethyl cellulose dimethyldiallylammonium chloride as the component (B) is preferably 0.005 to 0.5%, particularly 0.01 to 0.05% of the whole composition. When the content is less than 0.005%, the effect of suppressing the attachment of the plaque may not be satisfied satisfactorily. If it is more than 0.5%, sedimentation may occur to deteriorate the appearance stability (no sediment), or a pungent taste, a bitter taste, or an unusual taste derived therefrom may occur, and the feeling of use may be lowered.

(C)성분인 아네톨은, 안정화제로서 배합된다. 아네톨을 배합함으로써, 경시에서 앙금을 억제하여 외관 안정성을 향상시킬 수 있고, 또한 사용감(떫은맛·쓴맛·이상한맛의 없음)도 개선할 수 있다.Anethole, component (C), is incorporated as a stabilizer. By mixing anethole, it is possible to improve the appearance stability by suppressing sediment with time, and also to improve the usability feeling (bitter taste, bitter taste, no strange taste).

(C) 아네톨의 배합량은, 조성물 전체의 0.01 내지 0.2%, 특히 0.01 내지 0.1%가 바람직하다. 배합량이 0.01% 미만에서는, 외관 안정성(앙금의 없음)을 만족하게 향상할 수가 없는 경우가 있다. 또한, 사용감(떫은맛·쓴맛·이상한맛의 없음)을 개선할 수가 없는 경우가 있다. 0.2%를 초과하면, 외관 안정성(앙금의 없음)을 손상시키거나, 사용감(이상한맛)이 저하되는 경우가 있다.The blending amount of (C) anethole is preferably 0.01 to 0.2%, particularly 0.01 to 0.1%, based on the whole composition. If the blending amount is less than 0.01%, the appearance stability (no sediment) can not be satisfactorily improved. In addition, there is a case that the feeling of use (no bitter taste, bitter taste, or unusual taste) can not be improved. If it exceeds 0.2%, the appearance stability (no sediment) may be impaired and the feeling of use (odd taste) may be lowered.

본 발명에서는, (C)성분/[(A)성분+(B)성분]이 질량비로서 0.1 내지 10이고, 바람직하게는 0.2 내지 2이다. (C)성분을 (A) 및 (B)성분에 대해 상기 비율로 배합함으로써, (A) 및 (B)성분인 배합에 의한 앙금의 발생을 억제하여 제제의 외관 안정성을 향상할 수 있고, 또한 사용감도 개선할 수 있다. 0.1 미만에서는, 떫은맛, 쓴맛, 이상한맛 등이 생기고, 기호성을 양호하게 유지하고 앙금을 억제할 수 있지 않고, 10을 초과하면 외관 안정성(앙금의 없음)이 손상된다.In the present invention, the mass ratio of the component (C) / [component (A) + component (B)] is 0.1 to 10, preferably 0.2 to 2. By combining the components (A) and (B) in the above-described proportions, the appearance stability of the preparation can be improved by suppressing the occurrence of sedimentation due to the combination of components (A) and (B) The feeling of use can be improved. When the content is less than 0.1, a pungent taste, a bitter taste, an odd taste and the like are produced, the palatability is kept good and the sediment can not be suppressed, and if it exceeds 10, the appearance stability (no sediment) is damaged.

본 발명에서는, (C) 아네톨과 함께 (D) 다가알코올 및/또는 (E) 비이온성 계면활성제를 배합함으로써, (A) 및 (B)성분을 안정화 배합할 수 있고, 외관 안정성을 높일 수 있다. (D), (E)성분은, 어느 하나를 배합하여도, 또는 효과 발현의 점에서 (D) 및 (E)성분을 병용하여도 좋다.In the present invention, by blending (D) a polyhydric alcohol and / or (E) a nonionic surfactant together with (C) anethole, the components (A) and (B) can be stabilized and the appearance stability have. Any of the components (D) and (E) may be blended, or the components (D) and (E) may be used in combination in view of effect.

(D) 다가알코올로서는, 예를 들면 프로필렌글리콜, 글리세린, 크실리톨, 소르비트 에틸렌글리콜, 폴리에틸렌글리콜400 등의 폴리에틸렌글리콜, 폴리프로필렌글리콜, 말티트, 락티트 등을 들 수 있고, 이들의 1종류를 단독으로 또는 2종류 이상을 혼합하여 사용할 수 있다.Examples of the polyhydric alcohol (D) include polyethylene glycol such as propylene glycol, glycerin, xylitol, sorbitol ethylene glycol and polyethylene glycol, polypropylene glycol, maltitol, and lactate. These may be used alone or in combination of two or more.

(D)성분인 다가알코올을 배합하는 경우는, 조성물 전체의 2 내지 20%, 특히 2 내지 15% 첨가하는 것이 바람직하다. 2% 미만에서는 외관 안정성(앙금의 없음)을 만족하게 개선할 수가 없는 경우가 있다. 20%를 초과하면 다가알코올 유래의 이상한맛이 생기고, 사용감(떫은맛·쓴맛·이상한맛의 없음)이 손상되는 경우가 있다.When the polyhydric alcohol as the component (D) is blended, it is preferable to add 2 to 20%, particularly 2 to 15%, of the whole composition. If it is less than 2%, the appearance stability (no sediment) can not be satisfactorily improved. If it exceeds 20%, a strange taste derived from a polyhydric alcohol may be produced, and a feeling of use (bitter taste, bitter taste, no abnormal taste) may be damaged.

(E) 비이온성 계면활성제로서는, 구강용 조성물에 통상 배합되는 것을 사용할 수 있지만, 폴리옥시에틸렌경화피마자유, 폴리옥시에틸렌알킬에테르, 데카글리세린모노지방산에스테르 등이 알맞게 사용할 수 있다. 예를 들면 에틸렌옥사이드의 평균부가몰수가 60 내지 100몰의 폴리옥시에틸렌경화피마자유, 알킬기의 탄소수가 16(세틸) 내지 18(스테아릴)이고 에틸렌옥사이드의 평균부가몰수가 20 내지 40몰의 폴리옥시에틸렌알킬에테르, 지방산의 탄소수가 12(라우린산) 내지 18(스테아린산), 특히 12 내지 14(미리스틴산)의 데카글리세린모노지방산에스테르 등이고, 이들로부터 선택된 1종 또는 2종 이상을 배합할 수 있다. 그중에서도, 치면에의 플라그의 부착 억제력 및 플라그 중의 뮤탄스균 살균력을 충분히 발휘시키는 점, 및 외관 안정성(앙금의 없음)의 점에서, 폴리옥시에틸렌경화피마자시유가 바람직하고, 특히 에틸렌옥사이드의 평균부가몰수가 60 내지 100몰의 것이 바람직하다. 에틸렌옥사이드의 평균부가몰수가 60몰 미만에서는, 50℃ 보존품에서 앙금이 발생하여 외관 안정성(앙금의 없음)이 손상되는 경우가 있고, 100몰을 초과하는 것은 일반적으로는 시판되고 있지 않다.As the nonionic surfactant (E), those conventionally used in oral compositions can be used, and polyoxyethylene hardened castor oil, polyoxyethylene alkyl ether, decaglycerol mono fatty acid ester and the like can be suitably used. (Cetyl) to 18 (stearyl) of the alkyl group and an average addition mole number of the ethylene oxide is 20 to 40 moles, the polyether polyol having an average addition mole number of ethylene oxide of 60 to 100 moles, Oxyethylene alkyl ethers, decaglycerol mono fatty acid esters of fatty acids having carbon numbers of 12 (lauric acid) to 18 (stearic acid), particularly 12 to 14 (myristic acid), and the like, . Among them, a polyoxyethylene hydrogenated castor oil is preferable from the viewpoints of exhibiting the ability to suppress the attachment of the plage to the tooth surface, the ability to sterilize the muscarinic bacteria in the plaque, and the appearance stability (no sediment) Is preferably 60 to 100 moles. When the average addition mole number of ethylene oxide is less than 60 moles, there is a case in which sedimentation occurs at the product stored at 50 ° C, and appearance stability (no sedimentation) is impaired, and those having a molecular weight exceeding 100 moles are not generally commercially available.

구체적으로는 하기한 시판품을 사용할 수 있다.Specifically, the following commercially available products can be used.

·폴리옥시에틸렌경화피마자유· Polyoxyethylene hydrogenated castor oil

닛꼬케미칼주사제의 NIKKOL HCO계, 니혼에멀션사제의 에마렉스HC계, 니치유샤제의 유니옥스HC계 등NIKKOL HCO system of Nikko Chemical Injection, Emarex HC system of Nihon Emulsion Co., Ltd., Uniox HC system of Nichiyusha Co., Ltd.

·폴리옥시에틸렌알킬에테르Polyoxyethylene alkyl ether

니혼에멀션주식회사제의 에마렉스100계, 에마렉스600계 등Emarex 100 series manufactured by Nihon Emulsion Co., Ltd., Emarex 600 series, etc.

·데카글리세린모노지방산에스테르· Decaglycerol mono fatty acid ester

닛꼬케미칼주사제의 NIKKOL Decagln계, 미쯔비시화학푸드사제의 료토( 등록상표)포리구리에스텔D시리즈 등NIKKOL Decagln series manufactured by Nikko Chemical Co., Ltd., and Pori Griester D series manufactured by Mitsubishi Chemical Foods Co., Ltd.

(E)성분인 비이온성 계면활성제를 배합하는 경우는, 조성물 전체의 0.3 내지 2%, 특히 0.5 내지 1% 첨가하는 것이 바람직하다. 0.3% 미만에서는 외관 안정성(앙금의 없음)을 개선할 수가 없는 경우가 있고, 2%를 초과하면 치면에의 플라그의 부착 억제력 및 플라그 중의 뮤탄스균 살균력이 만족하게 발휘되지 않는 경우가 있다. 또한 사용감이 저하되는 경우가 있다.When the nonionic surfactant as the component (E) is incorporated, 0.3 to 2%, particularly 0.5 to 1%, of the total composition is preferably added. If the content is less than 0.3%, the appearance stability (no sedimentation) can not be improved. If the content is more than 2%, the detachment of the plaque on the tooth surface and the microbicidal disinfecting power in the plaque may not be satisfied satisfactorily. Also, the feeling of use may be lowered.

본 발명의 액체 구강용 조성물은, 세구제, 구중(口中) 청량제, 나아가서는 칫솔로 브러싱하여 사용하는 액체 치마제, 치마 젤 등으로서 조제, 적용할 수 있고, 특히 세구제, 액체 치마제로서 알맞다.The liquid oral composition of the present invention can be prepared and applied as a curing agent, a mouth refreshing agent, a liquid skimming agent and a skim gel used by brushing with a toothbrush, and is particularly suitable as a curing agent or a liquid skimming agent .

본 발명 조성물에는, 그 제형(劑型) 등에 응하여, 본 발명의 효과를 손상시키지 않는 범위에서 상기 성분 이외에 적절한 공지의 임의 성분을 배합할 수 있다. 예를 들면, 습윤제, 증점제, 방부제, 감미제, (C)성분 이외의 항료, (E)성분 이외의 계면활성제, (A) 및 (B)성분 이외의 유효 성분, 착색료, pH 조정제 등을 배합할 수 있다. 또한, 연마제는 배합하지 않아도 좋다.In the composition of the present invention, in addition to the above-mentioned components, any well-known optional ingredients may be incorporated in accordance with the form of the composition and the like within a range not to impair the effect of the present invention. For example, a wetting agent, a thickener, a preservative, a sweetener, a colorant other than the component (C), a surfactant other than the component (E), an effective component other than the components (A) and (B) . The abrasive may not be blended.

습윤제로서는, 상기 (D)성분인 다가알코올을 배합하면 좋다.As the wetting agent, a polyhydric alcohol as component (D) may be added.

증점제로서는, 예를 들면 크산탄고무, 알긴산나트륨, 폴리비닐알코올, 히드록시에틸셀룰로스, 카라기난, 카르복시메틸셀룰로스나트륨, 폴리비닐피롤리돈 등을 들 수 있다. 이들 증점제의 배합량은, 통상, 조성물 전체의 0 내지 3%이다.Examples of the thickening agent include xanthan gum, sodium alginate, polyvinyl alcohol, hydroxyethylcellulose, carrageenan, carboxymethylcellulose sodium, polyvinylpyrrolidone, and the like. The blending amount of these thickeners is usually 0 to 3% of the whole composition.

방부제로서는, 안식향산나트륨, 메틸파라벤, 에틸파라벤, 프로필파라벤, 부틸파라벤 등의 파라벤류, 염화세틸피리디늄, 염산알킬디아미노에틸글리신, 소르빈산칼륨 등을 들 수 있다.Examples of the preservative include parabens such as sodium benzoate, methylparaben, ethylparaben, propylparaben and butylparaben, cetylpyridinium chloride, alkyldiaminoethylglycine hydrochloride, and potassium sorbate.

감미제로서는, 사카린, 사카린나트륨, 테비오사이드, 수크랄로스, 환원팔라티노스, 에리스리톨, 아스파르탐 등을 들 수 있다.Examples of the sweetening agent include saccharin, sodium saccharin, tebioside, sucralose, reduced palatinose, erythritol, aspartame, and the like.

항료로서는, 아네톨 이외의 것, 예를 들면 페퍼민트유, 스피어민트유, 유칼리유, 윈터그린유, 클로브유, 타임유, 세이지유, 카르다몬유, 로즈마리유, 마조람유, 레몬유, 너트메그유, 라벤더유, 파라크레스유 등의 천연 정유, 및 l-멘톨, l-카르본, 신나믹알데히도, 오렌지오일, 1,8-시네올, 메틸살리실레이, 오이게놀, 티몰, 리날로올, 리모넨, 멘톤, 멘틸아세테이트, 시트랄, 캠퍼, 보르네올, 피넨, 스필란톨 등의 상기 천연 정유중에 포함되는 항료 성분, 또한, 에틸아세테이트, 에틸부틸레이트, 이소아밀아세테이트, 헥산알, 헥센알, 메틸안트라닐레이트, 에틸메틸페닐글리시데이트, 벤츠알데히드, 바닐린, 에틸바닐린, 프라네올, 말톨, 에틸말톨, 감마/델타데카락톤, 감마/델타운데카락톤, N-에틸-p-멘탄-3-카르복사미드, 멘틸락테이트, 에틸렌글리콜-l-멘틸카보네이트 등의 항료 성분, 나아가서는, 몇가지의 항료 성분이나 천연 정유를 조합시켜서 이루어지는, 애플, 바나나, 스트로베리, 블루베리, 멜론, 비치, 파인애플, 그레이프, 무스카트, 와인, 체리, 스쿼시, 커피, 브랜디, 요구르트 등의 조합 프레이버의 1종 또는 2종 이상을 들 수 있다. 이들의 항료는, 조성물중 0.00001 내지 3%이고 본 발명의 효과를 방해하지 않는 범위에서 사용할 수 있다.Examples of the flavoring agent include those other than anethole such as peppermint oil, spearmint oil, eucalyptus oil, wintergreen oil, clove oil, time oil, sage oil, cardamon oil, rosemary oil, marjoram oil, lemon oil, Natural essential oils such as vegetable oils and paracrine oils and natural essential oils such as l-menthol, l-carboen, cinnamic aldehydo, orange oil, 1,8-cineol, methyl salicylate, A minor component such as ethyl acetate, ethyl butyrate, isoamyl acetate, hexanal, hexenal, methyl (meth) acrylate, isophorone diisocyanate and the like, which are contained in the natural essential oils such as limonene, menton, mentyl acetate, citral, camphor, borneol, pinene, But are not limited to, anthranilate, ethylmethylphenylglycidate, benzaldehyde, vanillin, ethyl vanillin, pran neol, maltol, ethyl maltol, gamma / delta decalactone, gamma / delta undecalactone, Amide, mesyllactate, ethylene glycol-1-menthylcarbo Fruit, such as apple, banana, strawberry, blueberry, melon, beach, pineapple, grape, muscat, wine, cherry, squash, coffee, brandy , Yogurt, and the like. These dyes may be used in the range of 0.00001 to 3% in the composition and not interfering with the effect of the present invention.

계면활성제로서는, 아니온성 계면활성제, 양성 계면활성제, 카티온성 계면활성제를 배합할 수 있고, 예를 들면 라우릴황산나트륨 등의 알킬황산염, 라우로일메틸타우린, 아실아미노산염, 도데실벤젠술폰산나트륨, α-술포지방산알킬에스테르·나트륨, 알킬인산에스테르염 등의 아니온성 계면활성제, 알킬디메틸아미노아세트산베타인, 지방산아미드프로필디메틸아미노 아미노산 베타인 등의 아미노산 베타인형 양성 계면활성제, N-지방산 아실-N-카르복시메틸-N-히드록시에틸에틸렌 디아민 염 등의 이미다졸린형 양성 계면활성제, N-지방산 아실-L-알기네토 소금 등의 아미노산형 계면활성제 등을 들는 것을 할 수 있다. 배합량은 통상 0 내지 5%이고, 특히 0.2 내지 2%가 바람직하다.As the surfactant, anionic surfactants, amphoteric surfactants and cationic surfactants can be added. Examples thereof include alkylsulfates such as sodium laurylsulfate, lauroylmethyltaurine, acylamino acid salts, sodium dodecylbenzenesulfonate, anionic surfactants such as alkyl sulfates of? -sulfo fatty acids, sodium salts and alkylphosphoric acid ester salts; amino acid betaine type amphoteric surfactants such as alkyldimethylaminoacetic acid betaine and fatty acid amidepropyldimethylaminoamino acid betaine; An imidazoline-type amphoteric surfactant such as carboxymethyl-N-hydroxyethylethylenediamine salt, and an amino acid-type surfactant such as N-fatty acid acyl-L-alginate salt. The blending amount is usually 0 to 5%, particularly preferably 0.2 to 2%.

유효 성분으로서는, 예를 들면 염산크로르헥시딘, 염산알킬디아미노에틸글리신액 등의 살균제, 트라넥삼산, 입실론아미노카프론산, 알란토인, 알란토인쿠로르히드록시알루미늄, 알란토인디히드록시알루미늄 등의 항염증제, 덱스트라나제, 아밀라제, 프로테아제, 무타나제, 리소자임, 용균 효소, 리텍엔자임 등의 효소, 불화나트륨, 모노플루오로인산나트륨, 불화제1주석 등의 불화물, 아줄렌, 염화리소자임, 아스코르빈산 등의 비타민C류, 디히드로콜레스테롤, 글리시레틴염류, 글리시레틴산류, 히드로콜레스테롤, 클로로필, 구리클로로필린나트륨, 타임, 황금, 정자, 하마멜리스 등의 식물 추출물, 글루콘산구리, 로페프타이드, 폴리인산나트륨, 수용성 무기 인산 화합물, 폴리비닐피롤리돈, 치석 방지제, 플라그 방지제, 질산칼륨, 젖산알루미늄 등을 첨가할 수 있다. 또한, 이들 다른 유효 성분의 배합량은, 본 발명의 효과를 방해하지 않는 범위에서 유효량으로 할 수 있다.Examples of effective components include antimicrobial agents such as chlorhexidine hydrochloride and alkyldiaminoethylglycine hydrochloride, antineoplastic agents such as tranexamic acid, epsilon aminocaproic acid, allantoin, allantoin hydrochloride aluminum and allantoin dihydroxy aluminum , Enzymes such as dextranase, amylase, protease, mutagen, lysozyme, lytic enzyme, reticence enzyme, sodium fluoride, sodium monofluorophosphate, fluoride such as 1 tin fluoride, azulene, lysozyme chloride, ascorbic acid Plant extracts such as vitamin C, dihydrocholesterol, glycyrrhetinic acid, glycyrrhetinic acid, hydrocholesterol, chlorophyll, copper chlorophyllin sodium, thyme, gold, sperm, and hammamelis, copper gluconate, Tid, sodium polyphosphate, water-soluble inorganic phosphate compound, polyvinylpyrrolidone, anti-calculus agent, anti-plaque agent, potassium nitrate, It can be added. The blending amount of these other active ingredients may be an effective amount within a range not hindering the effect of the present invention.

착색료로서, 청색1호, 녹색3호, 황색4호, 적색105호 등 안전성이 높은 수용성 색소를 첨가할 수 있다.As a coloring agent, a water-soluble coloring matter having a high safety such as Blue No. 1, Green No. 3, Yellow No. 4 or Red No. 105 may be added.

pH 조정제로서는, 프탈산, 인산, 구연산, 호박산, 아세트산, 푸마르산, 사과산, 탄산이나 그들의 칼륨염, 나트륨염 또는 암모늄염, 리보핵산이나 그 염류, 수산화나트륨 등의 1종 또는 2종 이상을 사용할 수 있고, 특히 인산, 구연산과 그들의 나트륨염을 조합시킨 것이 바람직하다. 이 경우, 본 발명의 액체 구강용 조성물은, 25℃에서의 pH를 5.5 내지 8.5로 조정하는 것이 바람직하고, 이 부근의 pH 조정제로서 인산2수소나트륨과 인산1수소나트륨, 또는 구연산과 구연산나트륨을 조합시킨 것을 사용할 수 있다.As the pH adjusting agent, one or two or more of phthalic acid, phosphoric acid, citric acid, succinic acid, acetic acid, fumaric acid, malic acid, carbonic acid or their potassium salt, sodium salt or ammonium salt, ribonucleic acid or its salt, sodium hydroxide, Particularly, a combination of phosphoric acid, citric acid and their sodium salt is preferable. In this case, it is preferable that the liquid oral composition of the present invention is adjusted to pH 5.5 to 8.5 at 25 ° C, and sodium dihydrogenphosphate and sodium dihydrogenphosphate, or citric acid and sodium citrate Can be used.

또한, 용매로서 정제수가 배합되지만, 그 배합량은 60% 이상, 특히 70% 이상으로 할 수 있다.In addition, purified water is added as a solvent, but the blending amount thereof can be 60% or more, particularly 70% or more.

본 발명의 액체 구강용 조성물은, 실질적으로 에탄올을 포함하지 않는 것이다. 여기에서, 「실질적으로 에탄올을 포함하지 않는다」는 것은, 조성물중의 에탄올량이 조성물 전체에 대해 바람직하게는 100ppm 이하, 보다 바람직하게는 50ppm 이하, 특히 바람직하게는 10ppm 이하의 것이고, 하한치는 0ppm이다. 또한, 본 발명의 액체 구강용 조성물은, 에탄올 무배합이지만, 조성물중에 배합되는 항료중에 원료 유래의 에탄올이 미량 함유된 경우가 있기 때문에, 이들의 이유를 고려하고 나서음, 항료중 등에 미량 함유된 에탄올 이외에 에탄올을 포함하지 않는 것이다.The liquid oral composition of the present invention is substantially free of ethanol. Here, the expression " substantially free of ethanol " means that the amount of ethanol in the composition is preferably 100 ppm or less, more preferably 50 ppm or less, particularly preferably 10 ppm or less, and the lower limit is 0 ppm . In addition, the liquid oral composition of the present invention is ethanol-free but may contain a trace amount of ethanol derived from the raw material in the antioxidant compounded in the composition. Therefore, considering these reasons, It does not contain ethanol in addition to ethanol.

실시례Example

이하, 실시례 및 비교례, 처방례를 나타내고, 본 발명을 구체적으로 설명하지만, 본 발명은 하기한 실시례로 제한되는 것이 아니다. 또한, 하기한 예에서 %는 특히 단서가 없는 한 모두 질량%를 나타낸다.Hereinafter, examples, comparative examples and formulations are shown and the present invention will be described in detail, but the present invention is not limited to the following examples. In the following examples,% represents mass% unless otherwise specified.

[실시례, 비교례][Practical example, comparative example]

표 1 내지 4에 표시하는 조성의 액체 구강용 조성물을 일상 방법에 의해 조제하고, 하기 평가를 행하였다. 결과를 표 1 내지 4에 표시한다.Liquid oral compositions having the compositions shown in Tables 1 to 4 were prepared by a routine method, and the following evaluations were carried out. The results are shown in Tables 1-4.

(I) 플라그 부착 억제 효과(I) Effect of preventing plaque adhesion

24웰멀티플레이트 중에 액체 구강용 조성물을 각각 2㎖씩 넣고, 경면 연마한 펜탁스사제 하이드록시아파타이트판(반경 0.35㎝×높이 0.35㎝ 이하, HAP판이라고 기재한다) 3장을 30초간 침지하였다.2 ml each of the liquid oral composition was put in a 24-well multiplate, and three mirror-polished hydroxyapatite plates (radius 0.35 cm x height 0.35 cm or less, HAP plate) made by Pentax Inc. were immersed for 30 seconds.

24웰멀티플레이트 중에, 스트렙토코쿠스 뮤탄스(Streptococcus mutans) 10449주를 파장 660nm로의 탁도(濁度)가 0.35가 되도록 분산시킨 완충액*1을 2㎖ 넣고, 상기 HAP판을 3장씩 침지하고, 37℃에서 2시간 정치(靜置)하여 세균을 부착시켰다. 다음에, 상기 HAP판을 취출하여 멸균수로 세정 후, 액체 배지(培地)*2 2㎖에 세정한 HAP판을 3장씩 37℃에서 8시간 침지하고, 부착균을 배양하였다. 증류수로 세정 후, 플라그 염색액으로 염색하고, 색차계로 a값을 측정하고, 상기 3장의 평균치를 산출하였다. 평가 기준은 이하와 같다.Into a 24-well multiplate, 2 mL of Streptococcus mutans 10449 strain buffer 1 * in which turbidity at a wavelength of 660 nm was dispersed to a degree of 0.35 was added, and the HAP plates were immersed in triplicate to obtain 37 Lt; 0 > C for 2 hours to adhere bacteria. Next, the HAP plate was taken out and washed with sterilized water, and the HAP plates washed in 2 ml of a liquid medium (culture medium) * 2 were immersed in three sheets at 37 占 폚 for 8 hours, and the adherent bacteria were cultured. Washed with distilled water, dyed with a flage dyeing solution, measured for a value in a colorimeter, and the average value of the three sheets was calculated. The evaluation criteria are as follows.

플라그의 부착 억제 효과의 평가 기준 :Evaluation criteria of plaque adhesion inhibition effect:

◎ : a값의 평균치가 5 미만?: Average value of a is less than 5

○ : a값의 평균치가 5 이상 7.5 미만○: Average value of a is 5 or more and less than 7.5

△ : a값의 평균치가 7.5 이상 10 미만?: Average value of a is 7.5 or more and less than 10

× : a값의 평균치가 10 이상X: average value of a value of 10 or more

*1 : 완충액의 조성* 1: Composition of buffer

염화칼륨(KCl) 3.37g, 인산2수소칼륨(KH2PO4) 0.14g, 염화칼슘(CaCl2) 0.11g, 염화마그네슘(MgCl2)0 .02g를 800㎖의 정제수에 녹이고, 수산화칼륨(KOH)으로 pH를 7.0으로 조정하고, 정제수로 전량이 1L이 되도록 메스업하였다.Dissolving the potassium chloride (KCl) 3.37g, potassium dihydrogenphosphate (KH 2 PO 4) 0.14g, calcium chloride (CaCl 2) 0.11g, magnesium chloride (MgCl 2) 0 .02g the 800㎖ purified water, potassium hydroxide (KOH) To adjust the pH to 7.0, and to make up the total volume to 1 L with purified water.

*2 : 액체 배지의 조성* 2: Composition of liquid medium

트립틱 소이 브로트(Tryptic Soy Broth) 3g, 수크로스(Sucrose) 0.5g에 정제수 100㎖을 가하여 용해시켰다. 3 g of tryptic soy broth, and 0.5 g of sucrose were dissolved in 100 ml of purified water.

(Ⅱ) 플라그 중의 뮤탄스균 살균력(II) Sterilization of mutans bacteria in plaque

플라그 중의 뮤탄스균 살균력의 평가 방법 :Evaluation method of mutant bactericidal activity in plaque:

라이온주식회사 오럴케어 연구소에서 계대 보존(동결 보존)하여 둔 악티노마이세스 나에슬룬디(Actinomyces naeslundii) T14V주, 푸소박테리움-누클리아툼(Fusobacterium nucleatum) ATCC10953주, 포르피로모나스 진지발리스(Porphyromonas gingivalis) W50주, 스트렙토코쿠스 뮤탄스(Streptococcus mutans) ATCC25175주의 각 균액 40㎕을 각각, 121℃에서 15분간 오토클레이브한 5㎎/ℓ 헤민(시그마알도리치사제) 및 1㎎/ℓ 비타민K(와코순약공업사제)를 포함하는 토드-헤위트-브로스(Becton and Dickinson사제)(THBHM*3) 4㎖에 첨가하고, 37℃에서 하룻밤 혐기 배양(80vol% 질소, 10vol% 2산화탄소, 10vol% 수소)하였다. 배양 후, 각 균액(4종)으로부터 300㎕을 채취하고, 각각 30㎖의 THBHM에 첨가하고, 다시 하룻밤 배양하였다. 재배양 후, 각 균액을 원심분리(10,000rpm, 10min)하여, 상청(上淸)을 폐기하였다. 각 침사(沈渣)(세균)에 대해 121℃에서 15분간 오토클레이브한 베살메디움무신 배지(BMM*4)를 첨가하고 재현탁한 후, 미리 BMM 1,000㎖을 넣은 배양조(직경 140㎜×높이 200㎜)에, 상기 각 균수가 각각 1×107개/㎖이 되도록 접종하고, 교반자(직경 10㎜×길이 51㎜)를 이용하여 교반(약 100rpm로 회전)하면서, 37℃, 혐기 조건하(95vol% 질소, 5vol% 2산화탄소)에서 하룻밤 배양하였다. 그 후, BMM을 100㎖/h의 속도로 공급함과 함께, 같은 속도로 배양액을 배출하였다. 상기 배양조로부터 배출된 배양액은, 액량이 300㎖로 유지되는 다른 배양조(직경 90㎜×높이 190㎜)에 연속으로 공급하였다.Actinomyces naeslundii T14V strain, Fusobacterium nucleatum ATCC 10953 strain, Lepidonia spp., Which has been stored (cryopreserved) in the Oral Care Research Center, (Sigma Aldrich), which was autoclaved at 121 ° C for 15 minutes, and 40 μl of each strain of Streptococcus mutans ATCC 25175 strain of Porphyromonas gingivalis W50 strain, Streptococcus mutans ATCC 25175, and 1 mg / Was added to 4 ml of Todd-Hewitt-broth (manufactured by Becton and Dickinson) (THBHM * 3 ) containing K (manufactured by Wako Pure Chemical Industries, Ltd.) and incubated overnight at 37 ° C (80 vol.% Nitrogen, 10 vol. 10 vol% hydrogen). After the cultivation, 300 μl of each of the mycorrhizal fluids (4 kinds) was collected, added to 30 ml of THBHM, and further cultured overnight. After cultivation, the supernatant was discarded by centrifugation (10,000 rpm, 10 min) of each bacterial liquid. (BMM * 4 ) autoclaved at 121 ° C for 15 minutes was added to each of the sediments (bacterium), and the cells were resuspended and cultured in a culture tank (diameter 140 mm × height 200 mm ) and in the respective bacterial counts each 1 × 10 7 gae / ㎖ to the inoculation, and the stirrer (diameter × length 10㎜ 51㎜) and stirred (while rotating at about 100rpm), 37 ℃, anaerobic conditions using ( 95 vol% nitrogen, 5 vol% carbon dioxide dioxide) overnight. Thereafter, BMM was supplied at a rate of 100 ml / h, and the culture liquid was discharged at the same rate. The culture liquid discharged from the culture tank was continuously supplied to another culture tank (90 mm in diameter × 190 mm in height) in which the liquid amount was maintained at 300 ml.

이 배양 조내의 회전반(약 80rpm로 회전)에는, 부착 담체(擔體)인 하이드록시아파타이트디스크(직경 7㎜×높이 3.5㎜)를 장착하고, 그 표면에 인공적으로 플라그를 형성시켰다.A hydroxyapatite disk (7 mm in diameter x 3.5 mm in height) as an attachment carrier was mounted on the turntable (rotating at about 80 rpm) in the culture tank, and a plaque was artificially formed on the surface thereof.

상기 방법에 의한 배양은 14일간 행하고, 후반의 7일간은 다음에 나타내는 처치를 행하였다. 즉, 1일 3회, 플라그가 부착한 하이드록시아파타이트디스크를 배양조로부터 취출하고, 각각을 각 샬레(직경 25㎜×높이 14㎜)에 옮기고, 시험 조성물 5g(실시례 및 비교례)로 30초간 침지하였다. 그 후, 생리 식염수 5g으로 3회 세정 후, 재차 배양조 내로 되돌렸다. 동 조작은 총계 7회 실시하였다.Cultivation by the above method was carried out for 14 days, and the following treatments were carried out for the next 7 days. Namely, the hydroxyapatite disks attached with the plaques were taken out from the culture tank three times a day, and each was transferred to each chalet (25 mm in diameter × 14 mm in height), and 5 g of the test composition (Example and Comparative Example) Lt; / RTI > Thereafter, after washing three times with 5 g of physiological saline, it was returned to the culture tank again. This operation was performed seven times in total.

배양 종료시에는, 시험 조성물의 플라그 중의 뮤탄스균 살균력을 평가하기 위해, 플라그를 4㎖의 생리 식염수를 첨가한 시험관(직경 13㎜×100㎜)에 옮겼다. 곧바로 초음파 파쇄(200㎂의 출력으로 10초간), 단계 희석(10배 희석을 6단계)을 행하고, 일상 방법으로 제작한 바시트라신 첨가 Mitis-Salivarius 한천 평판 배지*5에 각 균액을 도말(塗沫)하였다. 상기 평판 배지는, 육안으로 콜로니가 확인될 수 있을 때까지 혐기 배양(80vol% 질소, 10vol% 2산화탄소, 10vol% 수소)하였다. 각 평판 배지의 콜로니수를 카운트 후, 생균수을 산출하였다. 또한, 대조로서 시험 조성물 대신에 정제수를 사용하여 마찬가지 처치를 하고, 플라그 중의 생균수을 산출하였다. 정제수로 처치한 것의 생균수을 100%로 하였을 때의 각 시험 조성물로 처치한 것의 생균수의 비율을 측정하고, 이하의 기준으로 나타내였다.At the end of the culture, the plaque was transferred to a test tube (diameter 13 mm x 100 mm) to which 4 ml of physiological saline was added in order to evaluate the microbicidal disinfecting power in the plaque of the test composition. Each broth was applied onto the Mitis-Salivarius agar plate medium * 5 with bacitracin prepared by the usual method, and the broth was applied (step Respectively. The plate medium was anaerobically cultured (80 vol% nitrogen, 10 vol% carbon dioxide, 10 vol% hydrogen) until the colonies could be visually confirmed. After counting the number of colonies of each plate culture medium, viable cell counts were calculated. In addition, as a control, the same treatment was performed using purified water instead of the test composition to calculate the viable cell count in the plaque. The ratio of viable cell counts treated with each test composition when the viable cell count of the cells treated with purified water was regarded as 100% was measured and expressed by the following criteria.

평가 기준 :Evaluation standard :

◎ : 잔존 생균수 1% 미만◎: Less than 1% of remaining viable cells

○ : 잔존 생균수 1% 이상 10% 미만○: The number of remaining viable cells is 1% or more and less than 10%

△ : 잔존 생균수 10% 이상 50% 미만△: Number of remaining viable cells 10% or more and less than 50%

× : 잔존 생균수 50% 이상X: The number of remaining viable cells was 50% or more

*3 : THBHM의 조성(1리터중의 질량으로 나타낸다)* 3: Composition of THBHM (expressed in mass per liter)

토드-헤위트-브로스(Becton and Dickinson사제) 30g/ℓTodd-Hewitt-Broth (manufactured by Becton and Dickinson) 30 g / l

헤민(시그마알도리치사제) : 5㎎/ℓHemin (manufactured by Sigma-Aldrich): 5 mg / l

비타민K(와코순약공업사제) : 1㎎/ℓVitamin K (manufactured by Wako Pure Chemical Industries, Ltd.): 1 mg / l

정제수 : 나머지Purified Water: Rest

(전량이 1ℓ이 되도록 메스업하였다)(Mass-up to a total volume of 1 L)

*4 : BMM의 조성(1리터중의 질량으로 나타낸다)* 4: Composition of BMM (expressed in mass per liter)

프로테오스펩톤(Becton and Dickinson사제) : 2g/ℓProteose peptone (manufactured by Becton and Dickinson): 2 g / l

트립톤(Becton and Dickinson사제) : 1g/ℓTryptone (manufactured by Becton and Dickinson): 1 g / l

무틴(시그마알도리치사제) : 2.5g/ℓMoutin (manufactured by Sigma-Aldrich): 2.5 g / l

헤민(시그마알도리치사제) : 1㎎/ℓHemin (manufactured by Sigma-Aldrich): 1 mg / l

비타민K(와코순약공업사제) : 0.2㎎/ℓVitamin K (manufactured by Wako Pure Chemical Industries, Ltd.): 0.2 mg / l

KCl(와코순약공업사제) : 0.5g/ℓKCl (manufactured by Wako Pure Chemical Industries, Ltd.): 0.5 g / l

시스테인(와코순약공업사제) : 0.1g/ℓCysteine (manufactured by Wako Pure Chemical Industries, Ltd.): 0.1 g / l

정제수 : 나머지Purified Water: Rest

(전량이 1ℓ이 되도록 메스업하였다)(Mass-up to a total volume of 1 L)

*5 : 바시트라신 첨가 Mitis-Salivarius 한천 평판 배지의 1리터중의 조성* 5: Composition of 1 liter of Bacitracin-added Mitis-Salivarius agar plate medium

Mitis-Salivarius Agar(Becton and Dickinson사제) : 90g/ℓMitis-Salivarius Agar (manufactured by Becton and Dickinson): 90 g / l

바시트라신(시그마알도리치사제) : 200U/ℓBacitracin (manufactured by Sigma-Aldrich): 200 U / L

(바시트라신은 미리 1,000배 농도 200,000/ℓ의 수용액을 조제하고, MS agar를 오토클레이브 후, 약 50℃로 식힌 점에서 배지의 1/1,000량 첨가하였다)(Bacitracin was prepared by first preparing an aqueous solution having a concentration of 200,000 / L at 1,000-fold concentration, autoclaving MS agar, and adding 1/1000 of the medium at a temperature of about 50 DEG C after cooling)

(Ⅲ) 외관 안정성(앙금의 없음)(III) Appearance stability (no sediment)

외관 안정성의 평가 방법 :Evaluation method of appearance stability:

샘플(액체 구강용 조성물)을 만주량 500㎖의 무색 투명한 PET 용기(요시노공업소제)에 450㎖ 충전하고, 50℃ 항온조(상요전기사제, MPR-311)에 1개월 보존 후의 외관 안정성을 하기 기준에 준하여, 육안 판정하였다.450 mL of a colorless transparent PET container (Yoshino Kogyo Co., Ltd.) of 500 mL in a mortar was charged, and the appearance stability after storage for 1 month in a 50 ° C thermostatic chamber (MPO-311, manufactured by Sanyo Denki Co., Ltd.) , A visual judgment was made.

외관 안정성의 평가 기준 :Evaluation criteria for appearance stability:

◎ : 흔들어도 앙금이 전혀 인정되지 않는다.◎: No sediment is recognized even if shaking.

○ : 흔든 때에 극히 미소한 앙금이 인정되지만, 문제 없는 레벨이다.○: A very fine sediment is recognized at the time of shaking, but it is a problem-free level.

△ : 근소한 앙금이 인정된다.△: Slight sediment is recognized.

× : 상당한 앙금이 인정된다.X: Considerable sediment is recognized.

(Ⅳ) 사용감(떫은맛·쓴맛·이상한맛의 없음)(Ⅳ) Feeling of feeling (bitter taste, bitter taste, no strange taste)

샘플(액체 구강용 조성물) 약 10㎖을 입에 머금고, 30초간 입을 가신 후, 세구 후의 사용감에 관해 하기한 4단계로 평가하고, 10명의 평균점을 다음 기준에 준하여, ◎, ○, △, ×로 나타내였다.About 10 ml of the sample (liquid oral composition) was put in the mouth and the mouth was soaked for 30 seconds, and the feeling after use was evaluated in the following four steps. The average of 10 persons was evaluated as?,?,? X.

사용감의 평가 기준 :Evaluation criteria of feeling:

4점 : 떫은맛·쓴맛·이상한맛이 없었다.4 points: There was no bitter taste, bitter taste, strange taste.

3점 : 떫은맛·쓴맛·이상한맛이 거의 없었다.3 points: There was little bitter taste, bitter taste, strange taste.

2점 : 떫은맛·쓴맛·이상한맛이 약간 있고, 약간 사용하기 어려웠다.2 points: There was a bitter taste, bitter taste, strange taste, and it was difficult to use a little.

1점 : 떫은맛·쓴맛·이상한맛이 상당히 있고, 사용하는데 지장이 있다.1 point: It has a bitter taste, a bitter taste, a strange taste, and it has trouble to use.

사용감의 판정 기준 :Acceptance criteria:

◎ : 평균점 3.5점 이상 4.0점 이하◎: Average point 3.5 or more and 4.0 or less

○ : 평균점 3.0점 이상 3.5점 미만○: 3.0 points or more and less than 3.5 points

△ : 평균점 2.0점 이상 3.0점 미만△: Average point of 2.0 points or more and less than 3.0 points

× : 평균점 2.0점 미만X: Average point less than 2.0 point

또한, 각 예 중의 주된 사용 원료는 하기와 같다. 또한, 항료 조성물A에 관해서는 표 5 내지 11에The main raw materials in each example are as follows. Further, for the composition A of the present invention,

표시하는 바와 같다.As shown.

염화세틸피리디늄(와코순약공업사제)Cetylpyridinium chloride (manufactured by Wako Pure Chemical Industries, Ltd.)

염화벤제토늄(하이아민 1622 : 론사재팬사제)Benzenethonium chloride (Hiamine 1622: manufactured by Lonsa Japan)

히드록시에틸셀룰로스디메틸디알릴암모늄클로리드Hydroxyethylcellulose dimethyldiallylammonium chloride

(상품명 셀코트L-200 : 아크조 노벨 사제) (Trade name: Cellcoat L-200, manufactured by Akzo Nobel)

(상품명 셀코트H-100 : 아크조 노벨 사제) (Trade name: Cellcoat H-100, manufactured by Akzo Nobel)

레오가도KGP(염화O-[2-히드록시-3-(토리메틸암모니오)프로필]히드록시에틸셀룰로스 : 라이온(주)제)(Trade name, product of Lion Corporation) was added to the reaction mixture,

아네톨(와코순약공업사제)Anethole (manufactured by Wako Pure Chemical Industries, Ltd.)

폴리옥시에틸렌(100)경화피마자유(닛꼬케미칼주사제)Polyoxyethylene (100) hardened castor oil (Nikko Chemical Injection)

폴리옥시에틸렌(60)경화피마자유(닛꼬케미칼주사제)Polyoxyethylene (60) hardened castor oil (Nikko Chemical Injection)

프로필렌글리콜(아사히유리사제)Propylene glycol (manufactured by Asahi Glass Co., Ltd.)

글리세린(85%, 사카모토약품공업사제)Glycerin (85%, manufactured by Sakamoto Pharmaceutical Industry Co., Ltd.)

크실리톨(로켓·후루레사제)Xylitol (manufactured by Rocket Furure)

폴리옥시에틸렌(20)세틸에테르(상품명 에마렉스120, 니혼에멀션사제)Polyoxyethylene (20) cetyl ether (trade name: Emarex 120, manufactured by Nihon Emulsion Co., Ltd.)

구연산(후소화학사제)Citric acid (manufactured by Fuso Chemical)

구연산나트륨(후소화학사제)Sodium citrate (manufactured by Fusoh Chemical)

사카린나트륨(다이토우화학사제)Sodium saccharin (manufactured by Daito Chemicals)

폴리에틸렌글리콜400(니치유샤제)Polyethylene glycol 400 (Nichiyusha Co.)

[표 1][Table 1]

Figure 112013077928449-pct00001
Figure 112013077928449-pct00001

[표 2][Table 2]

Figure 112013077928449-pct00002
Figure 112013077928449-pct00002

[표 3][Table 3]

Figure 112013077928449-pct00003
Figure 112013077928449-pct00003

[표 4][Table 4]

Figure 112013077928449-pct00004
Figure 112013077928449-pct00004

표 1 내지 4의 결과로부터, (A) 카티온성 살균제 또는 (B) 히드록시에틸셀룰로스디메틸디알릴암모늄클로리드가 배합되지 않은 경우(비교례 1, 2, 6)는, 경시에서 앙금이 생기지 않고 외관 안정성은 양호하였지만, 플라그 부착 억제 효과와 플라그 중의 뮤탄스균 살균 효과와의 양 효과를 만족하게 이루지 않았다. 또한, (A) 및 (B)성분을 배합한 조성에서, (C) 아네톨, 또는 (D) 다가알코올 및 (E) 비이온성 계면활성제를 결여한 경우(비교례 3, 5), (C) 아네톨의 (A) 및 (B)성분에 대한 비율이 부적절한 경우(비교례 4)는, 모두 앙금 발생을 억제할 수가 없고 외관 안정성에 뒤떨어지고, 비교례 7에서는 아네톨 대신에 다른 공지의 항료를 배합하여도 앙금을 억제할 수가 없었다. 이들에 대해, 본 발명 조성물(실시례)은, 플라그 부착 억제 효과 및 플라그 중의 뮤탄스균 살균 효과에 우수하면서도, 50℃에서 1개월 보존하여도 앙금이 거의 없고 양호한 외관 안정성으로 되는 것, 나아가서는 떫은맛, 쓴맛, 이상한맛이 없고 사용감도 양호한 것을 알았다.From the results of Tables 1 to 4, it can be seen that when no cationic bactericide (A) or hydroxyethyl cellulose dimethyldiallylammonium chloride (B) is blended (Comparative Examples 1, 2 and 6) The appearance stability was good, but the effect of the plaque adhesion inhibiting effect and the mutans bactericidal effect in the plaque was not satisfied. (C) Anethole or (D) polyhydric alcohol and (E) nonionic surfactant were not contained (Comparative Examples 3 and 5), (C) In the case where the ratio of anethole to the components (A) and (B) is inadequate (Comparative Example 4), all of the precipitates can not be suppressed and the appearance stability is poor. In Comparative Example 7, It was not possible to suppress sediment even if it was blended. In contrast, the composition (Example) of the present invention is excellent in the effect of suppressing the attachment of plaque and the microbicidal effect of bacteria in plaques, and exhibits little sedimentation and good appearance stability even after storage at 50 占 폚 for one month, , No bitter taste, no strange taste, and good feeling.

[표 5][Table 5]

Figure 112013077928449-pct00005
Figure 112013077928449-pct00005

[표 6][Table 6]

Figure 112013077928449-pct00006
Figure 112013077928449-pct00006

주 ; 표중, 부(部)는 질량부(質量部)이다(이하, 마찬가지).NOTE; In the table, a part is a mass part (hereinafter the same).

[표 7][Table 7]

Figure 112013077928449-pct00007
Figure 112013077928449-pct00007

[표 8][Table 8]

Figure 112013077928449-pct00008
Figure 112013077928449-pct00008

[표 9][Table 9]

Figure 112013077928449-pct00009
Figure 112013077928449-pct00009

[표 10][Table 10]

Figure 112013077928449-pct00010
Figure 112013077928449-pct00010

[표 11][Table 11]

Figure 112013077928449-pct00011
Figure 112013077928449-pct00011

다음에, 하기 처방례의 액체 구강용 조성물을 마찬가지로 조제하고 평가하였다. 이들 조성물은, 플라그 부착 억제 효과, 플라그 중의 뮤탄스균 살균력, 외관 안정성 및 사용감이 우수하였다.Next, the liquid oral composition of the following formulation was similarly prepared and evaluated. These compositions were excellent in the effect of suppressing the attachment of plaque, the sterilizing power of the mutans bacteria in the plaque, the appearance stability and feeling of use.

[처방례 1][Prescription Example 1]

염화세틸피리디늄 0.05%Cetylpyridinium chloride 0.05%

염화벤제토늄 0.010.01 benzethonium chloride

히드록시에틸셀룰로스디메틸디알릴암모늄클로리드(셀코트L-200) 0.01Hydroxyethylcellulose dimethyldiallylammonium chloride (Cellcoat L-200) 0.01

아네톨 0.05Anethole 0.05

폴리옥시에틸렌경화피마자유(100) 0.5Polyoxyethylene hydrogenated castor oil (100) 0.5

프로필렌글리콜 3Propylene glycol 3

글리세린 4.5Glycerin 4.5

크실리톨 3Xylitol 3

구연산 0.03Citric acid 0.03

구연산나트륨 0.25Sodium citrate 0.25

사카린나트륨 0.004Saccharin sodium 0.004

정제수Purified water 밸런스                                                     balance

계 100.0%Total 100.0%

(C)성분/[(A)성분+(B)성분]=0.71(C) / [(A) + (B)] = 0.71

[처방례 2][Prescription Example 2]

염화벤제토늄 0.01%0.01% benzethonium chloride

히드록시에틸셀룰로스디메틸디알릴암모늄클로리드(셀코트L-200) 0.01Hydroxyethylcellulose dimethyldiallylammonium chloride (Cellcoat L-200) 0.01

아네톨 0.05Anethole 0.05

폴리옥시에틸렌경화피마자유(100) 0.5Polyoxyethylene hydrogenated castor oil (100) 0.5

프로필렌글리콜 3Propylene glycol 3

글리세린 4.5Glycerin 4.5

크실리톨 3Xylitol 3

구연산 0.03Citric acid 0.03

구연산나트륨 0.25Sodium citrate 0.25

사카린나트륨 0.004Saccharin sodium 0.004

정제수Purified water 밸런스                                                     balance

계 100.0%Total 100.0%

(C)성분/[(A)성분+(B)성분](C) component / [(A) component + (B) component]

=2.5= 2.5

[처방례 3][Prescription Example 3]

염화세틸피리디늄 0.05%Cetylpyridinium chloride 0.05%

히드록시에틸셀룰로스디메틸디알릴암모늄클로리드(셀코트L-200) 0.01Hydroxyethylcellulose dimethyldiallylammonium chloride (Cellcoat L-200) 0.01

아네톨 0.05Anethole 0.05

폴리옥시에틸렌경화피마자유(80) 0.5Polyoxyethylene hydrogenated castor oil (80) 0.5

프로필렌글리콜 3Propylene glycol 3

글리세린 4.5Glycerin 4.5

크실리톨 3Xylitol 3

구연산 0.03Citric acid 0.03

구연산나트륨 0.25Sodium citrate 0.25

사카린나트륨 0.004Saccharin sodium 0.004

정제수Purified water 밸런스                                                      balance

계 100.0%Total 100.0%

(C)성분/[(A)성분+(B)성분]=0.83(C) / [(A) + (B)] = 0.83

[처방례 4][Prescription Example 4]

염화세틸피리디늄 0.05%Cetylpyridinium chloride 0.05%

히드록시에틸셀룰로스디메틸디알릴암모늄클로리드(셀코트L-200) 0.01Hydroxyethylcellulose dimethyldiallylammonium chloride (Cellcoat L-200) 0.01

아네톨 0.05Anethole 0.05

폴리옥시에틸렌경화피마자유(100) 0.5Polyoxyethylene hydrogenated castor oil (100) 0.5

프로필렌글리콜 3Propylene glycol 3

글리세린 4.5Glycerin 4.5

폴리에틸렌글리콜400 4Polyethylene glycol 400 4

구연산 0.03Citric acid 0.03

구연산나트륨 0.25Sodium citrate 0.25

사카린나트륨 0.004Saccharin sodium 0.004

정제수Purified water 밸런스                                                      balance

계 100.0%Total 100.0%

(C)성분/[(A)성분+(B)성분]=0.83(C) / [(A) + (B)] = 0.83

Claims (7)

조성물 중의 에탄올량이 100ppm 이하인 액체 구강용 조성물에,
(A) 염화세틸피리디늄, 염화벤제토늄 및 염화벤잘코늄에서 선택되는 1종 또는 2종 이상인 카티온성 살균제 0.02~0.05질량% 및
(B) 히드록시에틸셀룰로스디메틸디알릴암모늄클로리드를 0.01~0.05질량% 배합함과 함께,
(C) 아네톨을 0.01~0.1질량%, 또한 (C)성분/[(A)성분+(B)성분]이 질량비로서 0.2~2가 되는 범위에서 병용하고, 또한
(D) 다가알코올 2~15질량% 및/또는 (E) 비이온성 계면활성제 0.5~1질량%를 배합한 것을 특징으로 하는 액체 구강용 조성물.
In the liquid oral composition wherein the amount of ethanol in the composition is 100 ppm or less,
(A) 0.02 to 0.05 mass% of at least one cationic fungicide selected from cetylpyridinium chloride, benzethonium chloride and benzalkonium chloride, and
(B) hydroxyethyl cellulose dimethyldiallylammonium chloride in an amount of 0.01 to 0.05 mass%
(C) anethole in an amount of from 0.01 to 0.1% by mass, and the component (C) / (component (A) + component (B)
(D) 2 to 15% by mass of a polyhydric alcohol and / or (E) 0.5 to 1% by mass of a nonionic surfactant.
제1항에 있어서,
(A) 카티온성 살균제가 염화세틸피리디늄인 것을 특징으로 하는 액체 구강용 조성물.
The method according to claim 1,
(A) a liquid oral composition characterized in that the cationic bactericide is cetylpyridinium chloride.
제1항 또는 제2항에 있어서,
(E) 비이온성 계면활성제가 폴리옥시에틸렌경화피마자유인 것을 특징으로 하는 액체 구강용 조성물.
3. The method according to claim 1 or 2,
Wherein the nonionic surfactant (E) is a polyoxyethylene hydrogenated castor oil.
조성물 중의 에탄올량이 100ppm 이하인 액체 구강용 조성물에, (A) 염화세틸피리디늄, 염화벤제토늄 및 염화벤잘코늄에서 선택되는 1종 또는 2종 이상인 카티온성 살균제 0.02~0.05질량% 및 (B) 히드록시에틸셀룰로스디메틸디알릴암모늄클로리드를 0.01~0.05질량% 배합함과 함께, (C) 아네톨을 0.01~0.1질량%, 또한 (C)성분/[(A)성분+(B)성분]이 질량비로서 0.2~2가 되는 범위에서 병용하고, 또한 (D) 다가알코올 2~15질량% 및/또는 (E) 비이온성 계면활성제 0.5~1질량%를 배합하여,
상기 액체 구강용 조성물에 (A) 및 (B)성분을 안정화 배합하는 것을 특징으로 하는 제조 방법.
(A) 0.02 to 0.05 mass% of at least one cationic fungicide selected from cetylpyridinium chloride, benzethonium chloride and benzalkonium chloride, and (B) at least one compound selected from the group consisting of hydroxy (C) an anthole in an amount of 0.01 to 0.1 mass% and a component (C) / [component (A) + component (B)] in an amount of 0.01 to 0.05 mass% (D) 2 to 15% by mass of a polyhydric alcohol and / or (E) 0.5 to 1% by mass of a nonionic surfactant are blended in the range of 0.2 to 2,
Wherein the components (A) and (B) are stabilized and formulated in the liquid oral composition.
삭제delete 삭제delete 삭제delete
KR1020137022621A 2011-03-25 2012-03-01 Liquid composition for oral cavity and method for stable addition of components to composition KR101936969B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011067845A JP5853387B2 (en) 2011-03-25 2011-03-25 Liquid oral composition and method for stabilizing and blending ingredients into the composition
JPJP-P-2011-067845 2011-03-25
PCT/JP2012/055170 WO2012132747A1 (en) 2011-03-25 2012-03-01 Liquid composition for oral cavity and method for stable addition of components to composition

Publications (2)

Publication Number Publication Date
KR20140007406A KR20140007406A (en) 2014-01-17
KR101936969B1 true KR101936969B1 (en) 2019-01-09

Family

ID=46930494

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137022621A KR101936969B1 (en) 2011-03-25 2012-03-01 Liquid composition for oral cavity and method for stable addition of components to composition

Country Status (5)

Country Link
JP (1) JP5853387B2 (en)
KR (1) KR101936969B1 (en)
CN (1) CN103458864B (en)
MY (1) MY164603A (en)
WO (1) WO2012132747A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2775995B1 (en) * 2011-11-09 2017-07-05 Colgate-Palmolive Company Alcohol-free mouthwash
US9125841B2 (en) * 2013-02-26 2015-09-08 Johnson & Johnson Consumer Inc. Oral care compositions
CN106999371A (en) 2014-12-01 2017-08-01 高露洁-棕榄公司 Improve micro- robustness
JP6413815B2 (en) * 2015-02-06 2018-10-31 ライオン株式会社 Liquid oral composition
KR102337307B1 (en) 2017-04-10 2021-12-09 (주)아모레퍼시픽 Low irritating oral composition
JP7143198B2 (en) * 2018-12-03 2022-09-28 サンスター株式会社 oral composition
EP4106716A4 (en) * 2020-02-18 2024-03-13 Sunstar Americas Inc Oral care composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3890395A (en) * 1994-11-17 1996-06-17 Warner-Lambert Company Antimicrobial oral compositions
JPH11255629A (en) * 1998-01-08 1999-09-21 Sunstar Inc Composition for oral cavity
JP2001139442A (en) * 1999-08-27 2001-05-22 Lion Corp Liquid composition for oral cavity
JP4496420B2 (en) * 1999-12-08 2010-07-07 ライオン株式会社 Dentifrice composition
EP1236461A1 (en) * 1999-12-08 2002-09-04 Lion Corporation Toothpaste compositions
JP4539796B2 (en) * 1999-12-08 2010-09-08 ライオン株式会社 Dentifrice composition
JP4985905B2 (en) * 2005-07-29 2012-07-25 ライオン株式会社 Liquid oral composition and l-menthol precipitation prevention method
JPWO2007066497A1 (en) * 2005-12-09 2009-05-14 ライオン株式会社 Dentifrice composition
JP2008120753A (en) * 2006-11-14 2008-05-29 Sunstar Inc Liquid composition for oral cavity
JP5682283B2 (en) * 2009-12-25 2015-03-11 ライオン株式会社 Liquid oral composition

Also Published As

Publication number Publication date
WO2012132747A1 (en) 2012-10-04
MY164603A (en) 2018-01-30
JP5853387B2 (en) 2016-02-09
CN103458864B (en) 2016-08-17
JP2012201632A (en) 2012-10-22
KR20140007406A (en) 2014-01-17
CN103458864A (en) 2013-12-18

Similar Documents

Publication Publication Date Title
KR101936969B1 (en) Liquid composition for oral cavity and method for stable addition of components to composition
KR101380508B1 (en) Liquid oral composition containing isopropylmethylphenol
JP5470837B2 (en) Liquid oral composition
KR101851399B1 (en) Oral composition
JP4591680B2 (en) Liquid oral composition
KR101523401B1 (en) Liquid oral composition, and method for improvement in bactericidal activity of cationic bactericidal agent
JP4957882B2 (en) Ethanol-free mouthwash composition
JP5552725B2 (en) Oral composition and oral biofilm disinfectant
JP5359546B2 (en) Liquid oral composition
KR20200093514A (en) Oral biofilm formation inhibitor and oral composition
KR20190139199A (en) Oral Biofilm Remover and Oral Composition
JP5682283B2 (en) Liquid oral composition
JP4873154B2 (en) Liquid oral composition
CN107205899B (en) Liquid oral composition
KR101820192B1 (en) Inhibitor of attachment of periodontal-disease-inducing bacterium onto surfaces of teeth, oral biofilm formation inhibitor, and composition for oral applications
KR101780837B1 (en) Emulsion-type liquid composition for oral cavity, and process for production thereof
KR102491340B1 (en) liquid oral composition
JP2007008843A (en) Dentifrice composition and method for preventing discoloration of dentifrice composition
KR101773227B1 (en) Dentrifice composition
JP2018095570A (en) Oral composition

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant